According to the Measures for the Administration of Information Disclosure of Listed Companies of the China Securities Regulatory Commission, the time limit for the disclosure of the semi-annual reports of listed companies is until August 30 of each year
.
According to the public information of listed companies, at least 10 pharmaceutical companies, including Ruizhi Pharmaceutical, Haixiang Pharmaceutical, Meinian Health, Lanfan Medical, Guangzheng Ophthalmology, Jilin Aodong, Yifan Pharmaceutical, etc.
, have caught up with the "last train"
disclosed in the 2022 semi-annual report.
Judging from the year-on-year increase in the net profit attributable to the mother of these pharmaceutical companies in the first half of the year, the performance of Wise Pharmaceutical is eye-catching, and the net profit of the pharmaceutical company increased by more than 10,000%
year-on-year.
Wise Pharmaceutical: Net profit increased by 18518.
34% year-on-year
Wise Pharmaceutical: Net profit increased by 18518.
34% year-on-year
In the first half of the year, Wise Pharmaceutical achieved operating income of 687 million yuan, a year-on-year decrease of 18.
75%; The net profit attributable to the shareholders of the listed company was 957 million yuan, an increase of 18518.
34%
year-on-year.
As for the reasons for the change in performance, the company said that it was mainly the investment income generated by the prebiotic business that led to a sharp increase in
net profit.
Haixiang Pharmaceutical: Net profit increased by 183.
71% year-on-year
Haixiang Pharmaceutical: Net profit increased by 183.
71% year-on-year
From January to June 2022, Haixiang Pharmaceutical achieved operating income of 1.
468 billion yuan, an increase of 23.
46% year-on-year, net profit attributable to shareholders of listed companies of 172 million yuan, an increase of 183.
71% year-on-year, and earnings per share of 0.
1100 yuan
.
Jiuzhitang: Net profit increased by 67.
81% year-on-year
Jiuzhitang: Net profit increased by 67.
81% year-on-year
From January to June 2022, Jiuzhitang achieved operating income of 1.
889 billion yuan, down 9.
10% year-on-year, and net profit attributable to shareholders of listed companies was 368 million yuan, an increase of 67.
81% year-on-year, and earnings per share was 0.
4305 yuan
.
Meinian Health: Net profit loss widened
Meinian Health: Net profit loss widened
From January to June 2022, Meinian Health achieved operating income of 2.
922 billion yuan, down 13.
67% year-on-year, and the net profit attributable to shareholders of listed companies was a loss of 666 million yuan, a loss of 56.
30% year-on-year, and earnings per share was -0.
1700 yuan
.
Blue Sail Medical: Net profit turned from profit to loss
Blue Sail Medical: Net profit turned from profit to loss
Blue Sail Medical's revenue in the first half of the year was about 2.
574 billion yuan, a year-on-year decrease of 50.
39%; The net loss was about 180 million yuan, compared with a net profit of about 344 million yuan in the same period last year, which turned from profit to loss
.
Guangzheng Ophthalmology: Net profit to profit and loss
Guangzheng Ophthalmology: Net profit to profit and loss
From January to June 2022, Guangzheng Ophthalmology achieved operating income of 341 million yuan, down 35.
38% year-on-year, and the net profit attributable to the shareholders of the listed company was a loss of 63.
6768 million yuan, a year-on-year take profit and loss, and the net profit of 61.
2849 million yuan and earnings per share in the same period last year was -0.
1200 yuan
.
Jilin Aodong: Net profit fell by 48.
60% year-on-year
Jilin Aodong: Net profit fell by 48.
60% year-on-year
In the first half of 2022, Jilin Aodong achieved operating income of 1.
250 billion yuan, an increase of 15.
47% year-on-year, net profit attributable to shareholders of listed companies was 495 million yuan, down 48.
60% year-on-year, and earnings per share was 0.
4345 yuan
.
Yifan Pharmaceutical: Net profit fell by 24.
67% year-on-year
Yifan Pharmaceutical: Net profit fell by 24.
67% year-on-year
From January to June 2022, Yifan Pharmaceutical achieved operating income of 1.
769 billion yuan, down 25.
58% year-on-year, and net profit attributable to shareholders of listed companies was 161 million yuan, down 24.
67% year-on-year, and earnings per share was 0.
1300 yuan
.
Xinhua Pharmaceutical: Net profit decreased by 2.
85% year-on-year
Xinhua Pharmaceutical: Net profit decreased by 2.
85% year-on-year
Xinhua Pharmaceutical's operating income in the first half of the year was about 3.
664 billion yuan, an increase of 3.
19% year-on-year; Net profit attributable to shareholders of listed companies was approximately RMB194 million, down 2.
85% year-on-year; Basic earnings per share were RMB0.
3, a decrease of 6.
25%
year-on-year.
Sinopharm Consistent: Net profit decreased by 9.
07% year-on-year
Sinopharm Consistent: Net profit decreased by 9.
07% year-on-year
Sinopharm's operating income in the first half of the year was 36.
129 billion yuan, an increase of 8.
94% year-on-year; Net profit attributable to shareholders of listed companies was RMB674 million, down 9.
07% year-on-year; Net profit attributable to shareholders of listed companies, net of non-recurring gains and losses, was RMB653 million, a decrease of 9.
45%
year-on-year.
Shuangcheng Pharmaceutical: Net profit turned from year to year
Shuangcheng Pharmaceutical: Net profit turned from year to year
Shuangcheng Pharmaceutical achieved operating income of 127 million yuan in the first half of the year, down 26.
98% year-on-year; The net profit attributable to the shareholders of the listed company was -1.
8138 million yuan, a year-on-year profit and loss
.
Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.
